1st Quarter - Amendment — CEPHEID for CEPHEID (2016)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$29,000

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
1st Quarter - Report	Aug 8, 2016	$42,000	Replaced
1st Quarter - Amendment (this page)	Aug 8, 2016	$29,000	Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Science/Technology SCI

molecular diagnostic tests, infection control platforms, regulation of laboratory tests, reimbursement for laboratory tests. antimicrobial resistance/antibiotic stewardship

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Centers For Disease Control & Prevention (CDC); White House Office; Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS)

Health Issues HCR

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance, antimicrobial resistance/antibiotic stewardship), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight of clinical laboratory tests, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues, disease specific issues (multi-drug resistant tuberculosis, infection)

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: SENATE; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Veterans Affairs, Dept of (VA); White House Office; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Medical/Disease Research/Clinical Labs MED

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); White House Office; Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.